Aligos Therapeutics Files 8-K on Financials
Ticker: ALGS · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations-update
Related Tickers: ALGS
TL;DR
ALGS filed an 8-K for financial updates, no specific numbers yet.
AI Summary
Aligos Therapeutics, Inc. filed an 8-K on March 10, 2025, to report on its results of operations and financial condition. The filing does not contain specific financial figures or operational updates in the provided text, but serves as a notification of these items.
Why It Matters
This filing indicates that Aligos Therapeutics is providing updates on its financial performance and operational status to the SEC and the public.
Risk Assessment
Risk Level: low — This is a routine filing to report on financial condition and results of operations, with no immediate negative or positive news indicated in the provided text.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- March 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Aligos Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Aligos Therapeutics, Inc.'s results of operations and financial condition.
On what date was this 8-K filing made or reported as of?
This 8-K filing was made as of March 10, 2025.
In which state is Aligos Therapeutics, Inc. incorporated?
Aligos Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Aligos Therapeutics, Inc.?
The principal executive office address is One Corporate Dr., 2nd Floor, South San Francisco, California 94080.
What is the SIC code for Aligos Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Aligos Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 regarding Aligos Therapeutics, Inc. (ALGS).